Khavinson Bioregulators & Mental Health

Modern psychiatry is brilliant at suppressing symptoms and terrible at repairing systems. SSRIs push on serotonin. Benzodiazepines sedate GABA. Antipsychotics and mood stabilizers clamp dopamine and voltage‑gated channels. These can be life‑saving in crisis—no question—but they don’t fix the organs and regulatory axes that determine how a human being sleeps, processes stress, generates energy, and experiences emotion.

Khavinson’s peptide bioregulators were developed from the opposite philosophy. Instead of “drugging receptors,” they aim to restore structure and function in specific tissues: the pineal gland, the cerebral cortex, the adrenal cortex, the ovaries and testes, the immune system. The Russian clinical work doesn’t talk about “Major Depressive Disorder” or “GAD.” Instead, it measures psycho‑emotional symptoms—irritability, tearfulness, anxiety, insomnia, fatigue, apathy, emotional instability—that line up with the symptom clusters modern psychiatry calls depression, anxiety, burnout, and post‑traumatic mood disorders.

This article translates that body of work into a single, ready‑to‑publish blueprint for mental‑health–oriented bioregulator use: what the trials actually showed, how they map to real‑world conditions, and where the safety and evidence boundaries sit.

---

1. Endoluten – Pineal, Circadian Rhythm & Mood Architecture

What it is A pineal‑derived peptide complex that targets pinealocytes, melatonin synthesis, and neuroendocrine integration between nervous, endocrine and immune systems.

Who was studied Across several cohorts (total n ≈ 163):

• Dyshormonal myocardiodystrophy
• Physiogenic asthenia (stress‑related exhaustion)
• Mild/moderate climacteric syndrome (perimenopausal/menopausal women)
• Oncology patients post‑surgery and chemo/radiation

Baseline psycho‑emotional symptoms included irritability, tearfulness, anxiety, insomnia, rapid fatigability, low work capacity, poor attention and memory, apathy and neurosis‑like asthenia.

Dosing Typically 1–2 capsules (10 mg) 2–3 times per day, for 15–60 days, depending on condition.

Key outcomes in climacteric women

Endoluten delivered large, statistically significant reductions in psycho‑emotional and vegetative symptoms:

• Irritability: 93.1% → 36.1%
• Tearfulness: 54.2% → 22.3%
• Sleep disturbances: 76.8% → 22.1%
• Rapid fatigue: 85.2% → 32.6%
• Low working capacity: 86.8% → 38.4%
• Hot flashes, sweating, tachycardia, and BP swings all fell sharply as well.
• Attention and memory measures improved meaningfully.

Patients reported a “considerable increase in working efficiency” explicitly tied to normalization of psycho‑emotional state. One to two months after the course, symptoms like dizziness, tinnitus, weakness and sleep disturbances had not relapsed.

Asthenia and oncology

• In men with physiogenic asthenia, Endoluten eliminated weakness, dizziness, high fatigability and sleep disturbances faster and more durably than standard therapy, with an after‑effect lasting 1–3 months post‑course.
• In oncology patients post‑chemo/radiation, it improved appetite, sleep, muscle tone and reduced apathy, while normalizing leukocytes, lymphocytes and T‑cell function.

Why this matters for depression & anxiety

Endoluten appears to recouple a triad that modern psychiatry often ignores: melatonin–cortisol circadian rhythm, immune function, and mood. Contemporary reviews show that disturbed melatonin cycles, blunted cortisol rhythms, immune‑inflammation and mitochondrial dysfunction are central features of major depressive and anxiety disorders.

In practical, clinical language: Endoluten is a plausible “circadian and psycho‑vegetative reset” for:

• Depression with severe insomnia, early‑morning waking, or chaotic sleep
• Seasonal affective symptom patterns
• Menopausal mood volatility and night sweats
• Post‑chemo “chemo‑brain” and flattening with sleep disruption

---

2. Cerluten – Brain Hardware, Cognition & Emotional Stability

What it is A brain‑derived peptide complex acting on cortical neurons and CNS tissue, with demonstrated EEG and cognitive effects.

Study population (n = 48; 37 controls)

• Long‑term consequences of craniocerebral injury (TBI) (1–10 years)
• Post‑stroke encephalopathy
• Vascular encephalopathy
• Non‑specific decline in mental capacity, memory and attention

All had previously received symptomatic and pathogenetic therapies that produced only short‑lived benefits and escalating dose requirements.

Dosing 1–2 capsules (10 mg) 2–3 times daily for 10–20 days.

Outcomes

Overall:

• “Good” result in 64.6% with Cerluten vs 27.0% under standard therapy; non‑responders 12.5% vs 32.5% respectively.

Symptom changes:

• Headaches: 76.6% → 34.1%
• Sleep disturbances: 54.9% → 24.3%
• Emotional instability: 75.8% → 21.4% (vs 43.0% in controls)
• Memory disturbance: 54.5% → 28.5%
• Absent‑mindedness: 48.7% → 14.6%
• Rapid fatigability: 72.0% → 32.4%

Objective measures:

• Attention tests: Patients processed more symbols with fewer errors and exhibited a clean “warm‑up then gradual decline” performance curve, characteristic of normalized attention and vigilance rather than chaotic fatigue.
• EEG: Patterns shifted from pathological types toward more normal alpha rhythms; zonal differences in the alpha rhythm re‑emerged; irritative activity and paroxysmal discharges were reduced or eliminated; the alpha index approached healthy norms more in the Cerluten group than in controls.

Trauma, mood, and why this is a big deal

Traumatic brain injury and stroke substantially increase the risk of later depression, emotional dysregulation, and anxiety. Independent randomized trials with the neurotrophic peptide Cerebrolysin in TBI patients have shown statistically significant reductions in depression and anxiety scores vs placebo, confirming that peptide‑based neurotrophics can directly improve post‑traumatic mood.

Cerluten demonstrates the same pattern in chronic TBI and vascular encephalopathy: it reduces emotional instability, improves sleep and cognition, normalizes EEG—hallmarks of post‑traumatic mood and anxiety syndromes, not just aging.

For trauma‑linked scenarios, Cerluten is the central “brain hardware repair” peptide for:

• Post‑TBI depression, anxiety, irritability and cognitive fog
• Mood and anxiety shifts after stroke or vascular brain damage
• Organic “anergic” or cognitive‑slowed depression when there is clear neurologic insult

It’s important to say plainly: PTSD in the DSM sense has not been directly trialed with Cerluten. The evidence base here is symptom‑domain overlap (emotional instability, sleep disturbance, cognitive impairment, irritability) in organic trauma populations, not formal PTSD diagnostic scales.

---

3. Glandokort – Adrenals, HPA Axis & Burnout Physiology

What it is A peptide complex from adrenal cortex tissue that supports adrenal steroidogenesis and stress adaptation.

Study population (n = 36; 26 controls)

• Chronic adrenal cortex insufficiency
• Long‑term occupational and psycho‑emotional stress

Baseline symptoms: general weakness, reduced appetite, headaches, sleep disturbances, increased irritability and apathy, reduced physical and mental performance.

Dosing 1 capsule (10 mg) twice daily with meals for 30 days.

Results

Subjective:

• Patients on Glandokort reported improved mood and sleep, higher physical and mental performance, and reduced irritability and apathy.

Endocrine:

• In adrenal insufficiency, aldosterone and 17‑ketosteroids increased from low to mid‑normal ranges, indicating restored adrenal metabolic activity.
• In chronically stressed subjects, cortisol and ACTH were at the lower limit of normal pre‑treatment—classic exhaustion of HPA reserves. After Glandokort, both cortisol and ACTH normalized, correlating tightly with symptom improvements.

Chronic stress, dysregulated cortisol, and blunted HPA responses are well‑established features of atypical depression, burnout, and certain anxiety phenotypes. Glandokort is directly reversing that biology.

This positions Glandokort as your HPA and burnout pillar for:

• Generalized anxiety with fatigue and stress intolerance
• “Executive burnout” depression—flat, exhausted, over‑caffeinated professionals
• Biological support during benzodiazepine or stimulant taper, where HPA resilience is often the bottleneck

---

4. Zhenoluten – Ovaries, Estradiol & Female Mood

What it is An ovarian peptide complex that modulates estradiol production and ovarian reserve.

Who was studied

• 39 women (45–53) with mild–moderate climacteric syndrome
• 28 women (38–43) with ovarian wasting (early climacteric)

Symptoms: hot flashes, sweats, BP swings, palpitations, chest pain, dizziness, weakness, plus irritability, tearfulness, anxiety, sleep disturbance, memory and attention problems, rapid fatigue, and low physical/mental performance.

Dosing 1 capsule (10 mg) twice per day with meals for 30 days.

Outcomes

• Marked reduction in hot flashes and vasomotor symptoms.
• Significant decreases in fast fatigue, reduced work capacity, and irritability and psycho‑emotional disturbances.
• Hormonal: FSH and LH dropped toward age‑norm lower ranges; LH/FSH ratio normalized; estradiol increased toward physiologic ranges. Symptom reductions tracked these hormonal shifts tightly.

Perimenopause and menopause are classic high‑risk windows for anxiety‑depression syndromes, with lowered estradiol directly impacting serotonin, dopamine, GABA systems and neuroplasticity. Zhenoluten is the root‑cause ovarian lever in stacks for:

• Menopausal/perimenopausal depression and anxiety
• PMDD‑like irritability, tearfulness, and insomnia
• Cognitive fog and mood lability tied to hormonal cycling

Combined with Endoluten (pineal) and Glandokort (adrenal), it gives a meaningful ovary–pineal–adrenal axis narrative for midlife women—a very different story from “you’re just low on serotonin.”

---

5. Testoluten – Testes, Testosterone & Male Midlife Mood

What it is A testicular peptide complex targeting Leydig/Sertoli cells and androgen production.

Population (n = 36; 14 controls, 22 Testoluten)

Men 47–65 with so‑called “male climacteric”:

• Rapid fatigue; reduced physical and mental performance
• Weak memory
• Emotional instability and irritability
• Sweating, BP spikes, headaches
• Sexual weakness and low libido

Dosing 1 capsule (10 mg) twice daily for 30 days.

Findings

• Hormonal: LH, FSH, and testosterone rose from low‑normal to mid‑normal in the Testoluten group; controls showed minimal changes.
• Clinical: significant improvement in emotional instability, irritability, cognitive efficiency, vegetative symptoms, and sexual function; all treated men reported increased libido.
• Semen: increased count and motility, fewer pathological forms, fewer leukocytes.

Hypogonadism and low‑T states are strongly associated with low mood, low energy, anhedonia, irritability and cognitive slowing in men. Testoluten directly addresses that underlying axis. Within your framework it is the male‑specific pillar for:

• Andropause‑related depression and anxiety
• “Midlife crash”—loss of drive, purpose, and vitality
• Low‑libido‑linked dysphoria and irritability

Stacked with Glandokort and Endoluten, it supports HPG + HPA + circadian systems that underlie most male midlife mental‑health complaints.

---

What the data can support

• Symptom‑level improvements in irritability, tearfulness, anxiety, insomnia, fatigue, apathy, cognitive complaints and emotional instability in defined clinical populations.
• Objective improvements in hormone panels, EEG patterns, and some cognitive tests.
• Good tolerability and absence of dependence or major side effects in the reported cohorts.

What the data cannot honestly support

• Claims that any Khavinson bioregulator “treats depression” or “cures PTSD” in the regulatory sense.
• Equivalence or superiority comparisons to SSRIs, mood stabilizers, antipsychotics, evidence‑based psychotherapy, or other first‑line psychiatric interventions.
• DIY self‑management of severe psychiatric illness without professional oversight.

Core disclaimer block (ready to drop under every protocol)

---

Within that frame, bioregulators can be presented honestly as what they are: an emerging toolset for organ‑level restoration (pineal, cortex, adrenals, ovaries, testes) that may, in research settings, shift the terrain on which mood, anxiety, and trauma symptoms arise—without pretending they replace the heavy machinery of modern psychiatry where it is truly needed.